Pharma-bio Serv (PBSV) Growth Rates Comparisons to Consulting Services Industry, Sector, Market. Sales, Income, EPS
CSIMarket
 
Pharma-Bio Serv, Inc.  (OTC: PBSV)
    Sector  Services    Industry Consulting Services
   Industry Consulting Services
   Sector  Services
 

Pharma-bio Serv Growth Comparisons

Select each growth Category to receive further Information





PBSV Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q4 MRQ) -7.13 % 1.83 % 6.19 % 9.17 %
Q / Q Revenue Growth (Q4 MRQ) 6.76 % -2.82 % 2.99 % 4.22 %
Y / Y Revenue Growth (for 12 months ending Q4 TTM) -8.08 % 4.18 % 34.07 % %
Sequential Revenue Growth (for 12 months ending Q4 TTM) -1.96 % 0.36 % 32.01 % 2.08 %
Revenue 5 Year Average Growth -14.33 % 7.51 % -0.1 % 10.85 %


PBSV's Growth Comparisons in I. Quarter 2026




Although the Consulting Services industry saw advancing Revenue by 1.83%, Pharma-bio Serv announced -7.13% year on year revenue decline in the first quarter 2026, to $ 2 millions, and underperformed the 6.19% Revenue growth in the Services sector. Weak first quarter revenue, in Consulting Services industry and within the Services sector, were reflected in Pharma-bio Serv, Inc. results which underperformed overall market.

Comparing the company's Revenue to the fourth quarter results, revenue were higher by 6.76% . On the yearly basis, average annual revenue growth for Pharma-bio Serv is -14.33%, while S & P 500's including only Businesses with the first quarter 2026 earnings, average annual revenue growth is 10.85% over the past five years.


Growth Rates of PBSV's Income in the first quarter 2026


PBSV Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q4 MRQ) - 8.98 % -13.82 % 29.95 %
Sequential Operating Income Change (Q4 MRQ) - -10.22 % 5.28 % 4.5 %
Y / Y Operating Income Growth (Q4 TTM) - -5.16 % 17.2 % 14.37 %
Sequential Operating Income Growth (Q4 TTM) - 0.82 % 16.48 % 6.96 %
Operating Income 5 Year Avg. Change - 6.6 % -14.05 % 27.51 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q4 MRQ) 287.06 % 48.06 % -30.26 % 21.83 %
Sequential Income from Cont. Ops. Change (Q4 MRQ) - -5.31 % -22.39 % 11.13 %
Y / Y Income from Cont. Ops. Change (Q4 TTM) - 8.01 % 0.15 % 16.46 %
Sequential Income from Cont. Ops. Change (Q4 TTM) - 6.84 % -2.28 % 6.05 %
Income from Cont. Ops. 5 Year Avg. Change - 7.45 % -6.62 % 32.4 %

PBSV Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q4 MRQ) 287.06 % 46.77 % -36.83 % 21.56 %
Q / Q Net Income Growth (Q4 MRQ) - -4.68 % -26.19 % 11.12 %
Y / Y Net Income Change (Q4 TTM) - 8.37 % -0 % 16.59 %
Sequential Net Income Change (Q4 TTM) - 6.97 % -2.69 % 6.03 %
Net Income 5 Year Avg. Growth - 7.45 % -6.63 % 32.35 %

PBSV's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q4 MRQ) - 28.01 % -30.26 % 21.83 %
Sequential EPS from Cont. Ops. Change (Q4 MRQ) - 34.9 % -22.39 % 11.13 %
Y / Y EPS from Cont. Ops. Change (Q4 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q4 TTM) - -11.37 % - -99.7 %
EPS from Cont. Ops. 5 Year Avg. Growth - 15.84 % -6.62 % 32.4 %



PBSV EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q4 MRQ) - 26.89 % -36.83 % 32.4 %
Q / Q EPS Net Growth (Q4 MRQ) - 35.8 % -26.19 % 11.12 %
Y / Y EPS Net Change (for 12 months ending Q4 TTM) - - - -99.97 %
Sequential EPS Net Change (for 12 months ending Q4 TTM) 0 % -12.67 % - -99.87 %
EPS Net 5 Year Avg. Change - 7.45 % -6.63 % 32.35 %



Pharma-bio Serv reported bottom-line of $ 0.00 in the first quarter, compare to $ 0.00 in the same quarter a year ago. Consulting Services industry grew by 26.89%, while Services sector decreased by -36.83%, and overall market improved by 21.56%.

Comparing company's EPS to the fourth quarter results, income per share were higher by 6.76% . On the yearly basis, average annual income per share growth for Pharma-bio Serv is -14.33%, while S & P 500's including only the businesses with the first quarter 2026 Results, average annual income per share growth is 32.35% over the past five years.

PBSV Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q4 MRQ) - 26.52 % 11.38 % 2 %
Sequential Free Cash Flow Change (Q4 MRQ) - 26.68 % -10.31 % 22.32 %
Y / Y Free Cash Flow Change (Q4 TTM) - -0.46 % 700.62 % 11.81 %
Sequential Free Cash Flow Change (Q4 TTM) - 11.01 % 617.08 % 2.41 %
Free Cash Flow 5 Year Avg. Change - 8.6 % -15.14 % 18.5 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q4 MRQ) - - - 1035.72 %
Sequential Net Cash Flow Change (Q4 MRQ) - 11.17 % 48.89 % -
Y / Y Net Cash Flow Change (Q4 TTM) - -13.41 % - -
Sequential Net Cash Flow Change (Q4 TTM) - - 2209.64 % -
Net Cash Flow 5 Year Avg. Change - - - 14.37 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q4 MRQ) - -12.52 % 6.46 % 23.41 %
Sequential Capital Expenditures Change (Q4 MRQ) - -69.08 % 10.35 % 18.97 %
Y / Y Capital Expenditures Change (Q4 TTM) - 37.87 % 61.46 % 23.88 %
Sequential Capital Expenditures Change (Q4 TTM) - -2.05 % 57.93 % 7.02 %
Capital Expenditures 5 Year Avg. Change - 0.88 % 1.64 % 11.92 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 







Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.